Ambrosia RT-CGM

Ambrosia Pioneers Affordable Real-Time CGM, Set to Transform Global Diabetes Management

In a significant development for diabetes care, Ambrosia has announced a groundbreaking advancement in real-time continuous glucose monitoring (CGM) technology. After extensive research, the company is poised to launch an innovative CGM system that promises to revolutionize affordability and accessibility in diabetes management.

Scheduled for release over the next 12 months(subject to FDA approvals), Ambrosia’s real-time CGM system will be priced at just $55 per month for individuals paying out-of-pocket. This strategic pricing model aims to dismantle the financial barriers that currently limit access to advanced diabetes care in economically disadvantaged regions.

Ambrosia’s new CGM system is not just a tool for monitoring glucose levels; it is a comprehensive health management platform. The device will provide continuous glucose readings every few minutes and includes critical features such as alarms for glucose level fluctuations and remote monitoring capabilities. Beyond these core functionalities, it will also offer insights into dietary impacts, stress levels, sleep patterns, and physical activity, making it a holistic health monitoring tool.

The introduction of this technology is particularly timely, as diabetes continues to be a global challenge. Over 450 million people worldwide are affected by type 2 diabetes, 25 million by type 1 diabetes, and nearly half a billion are at a pre-diabetic stage. Moreover, approximately 6% of all pregnancies are complicated by gestational diabetes. Current market leaders in CGM technology, including Abbott, Dexcom, Medtronic, and Senseonics, have made significant strides in managing the disease, but the high cost of their devices puts them out of reach for many.

The lack of affordable healthcare solutions has led to poor diabetes management, contributing to decreased life expectancy. By setting a new benchmark for pricing, Ambrosia hopes to not only expand access to diabetes care but also to compel other companies to reconsider their pricing strategies, potentially driving down global prices and making these life-saving devices accessible to a broader population.

Moreover, Ambrosia is planning to collaborate with diabetes management companies worldwide. This partnership will enable these companies to enhance their services, offering more comprehensive care packages to their members. Such collaborations are expected to improve overall health outcomes and support the global fight against diabetes.

Ambrosia’s initiative represents a major step forward in making advanced healthcare technologies accessible and affordable. It holds the promise of enabling better diabetes management for millions of people, ultimately contributing to longer and healthier lives.

#Ambrosia #CGM #AmbrosiaCGM #AmbrosiaARing #Abbott #Dexcom #Medtronic #Senseonics #Longevity #AgingWell #LifespanExtension #HealthyAging #LifeExtension #WellnessInnovation #DiabetesCare #HealthTech #CGM #AffordableHealthcare #DigitalHealth #InnovationInHealth #GlobalHealth #DiabetesTechnology #HealthcareSolutions #DiabetesCare #HealthTech #CGM #AffordableHealthcare #GlobalHealth #InnovationInHealth #Longevity

Disclaimer: Freestyle libre Sensor is a trademark of Abbott Diabetes Care Inc.
Ambrosia Systems Inc. does not have any Partnership Agreement or any kind of relationship with Abbott Diabetic Care or Abbott Laboratories.
Ambrosia apps and device are not FDA approved. Hence, do not use the glucose readings to take any medical decisions.

    Your Cart
    Your cart is emptyReturn to Shop